Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Genexine, Inc. clinical trials
The registry lists 36 studies whose lead sponsor is Genexine, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 22, 2026.
Keep track of what changes. Save the Genexine, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Genexine, Inc..
- Genexine, Inc.36 studiesSame company
Something wrong?
Related but not counted here: PT Kalbe Genexine Biologics (affiliate).
Studies
Recruiting first, then most recently updated. Showing 36 of 36.
- A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on DialysisRecruitingNCT06466785Phase 3
- Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck CancerCompletedNCT02079324Phase 1
- Clinical Trial of Efepoetin Alfa in Healthy SubjectsCompletedNCT06490939Phase 1
- Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy AdultsTerminatedNCT04445389Phase 1/2
- Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy AdultsCompletedNCT04715997Phase 1/2
- The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical CancerCompletedNCT03444376Phase 1/2
- Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)CompletedNCT03752723Phase 1/2
- Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly IndividualsCompletedNCT04915989Phase 1
- GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) PatientsActive, not recruitingNCT05191784Phase 2
- Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19TerminatedNCT04730427Phase 1
- Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 VaccinesWithdrawnNCT05067946Phase 2/3
- Individual Patient Compassionate Use of GX-I7No longer availableNCT04289155
- Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed GlioblastomaWithdrawnNCT04065087Phase 1/2
- Safety and Tolerability of GX-P1 in Healthy Male VolunteersCompletedNCT04298749Phase 1
- Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With GlioblastomaCompletedNCT03619239Phase 1
- Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy PatientsCompletedNCT03276988Phase 1/2
- GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid TumorsCompletedNCT03733587Phase 1
- Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT03478995Phase 1
- Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone DeficiencyCompletedNCT03309891Phase 2
- A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes MellitusStatus unknownNCT03962010Phase 2
- Safety and Tolerability of GX-I7 in HPV-infected Female VolunteersCompletedNCT03144934Phase 1
- Clinical Trial of GX-I7 in Healthy VolunteersCompletedNCT02860715Phase 1
- Safety and Tolerability of GX-G6 in Healthy Male SubjectsCompletedNCT03651466Phase 1
- Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)CompletedNCT02044653Phase 2
- A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9CompletedNCT02946606Phase 2
- Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial NeoplasiaCompletedNCT02139267Phase 2
- Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)Status unknownNCT02596243Phase 2
- Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After ObservationStatus unknownNCT02411019
- Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After ObservationStatus unknownNCT02100085
- Phase I Study GX-G3 in Healthy SubjectsCompletedNCT01951027Phase 1
- Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy SubjectsCompletedNCT02291991Phase 1
- Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3CompletedNCT01634503Phase 1
- Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110ECompletedNCT01813487Not applicable
- Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B PatientsCompletedNCT01641536Phase 1
- Phase I Study to Investigate the Safety and Efficacy of HBV DNA VaccineCompletedNCT00513968Phase 1
- Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected PatientsStatus unknownNCT00517569Phase 1